Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography

Table 2 Demographics

Syndromic diagnosis	CBS-PIB + (number = 11)	CBS-PIB - (number = 14)	NC (number = 26)	P	*Post hoc*
Age at PET	66.9 ± 5.5	65.8 ± 8.8	70.2 ± 2.9	0.054
Age at MRI	67.2 ± 5.2	66.1 ± 9.3 (n = 13)		0.110
Age at first clinic visit	65.6 ± 9.1	66.5 ± 5.1	n/a	0.750
Male: Female	6:5	6:8	14:12	0.810
Education, years	15.7 ± 2.2	15.8 ± 2.4	17.3 ± 2.0	0.620
MMSE	22.9 ± 6.3	22.4 ± 6.9	29.2 ± 1.2	0.0001	CBS-PIB+ vs NC P <0.05,
MMSE	22.9 ± 6.3	22.4 ± 6.9	29.2 ± 1.2	0.0001	CBS-PIB- vs NC P <0.01
CDR	0.7 ± 0.5	0.9 ± 0.6	n/a	0.830
CDR-SB	4.7 ± 3.2	3.7 ± 2.6	n/a	0.400
APOE4 (0,1,2)	4, 6, 0 (n = 10)	9, 1, 0 (n = 10)	17, 8, 1	0.066	CBS-PIB+ vs CBS-PIB- P < 0.05

CBS-PIB+, Corticobasal syndrome positive for Pittsburgh compound B; CBS-PIB-, Corticobasal syndrome negative for Pittsburgh compound B; CDR, Clinical Dementia Rating; CDR-SB, Clinical Dementia Rating sum of boxes; MMSE, Mini-mental State Examination; n/a, not applicable; NC, normal control. Data are mean ± standard deviation.

ISSN: 1758-9193